273 related articles for article (PubMed ID: 34385364)
1. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
Aletaha D; Westhovens R; Gaujoux-Viala C; Adami G; Matsumoto A; Bird P; Messina OD; Buch MH; Bartok B; Yin Z; Guo Y; Hendrikx T; Burmester GR
RMD Open; 2021 Aug; 7(2):. PubMed ID: 34385364
[TBL] [Abstract][Full Text] [Related]
2. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Westhovens R; Rigby WFC; van der Heijde D; Ching DWT; Stohl W; Kay J; Chopra A; Bartok B; Matzkies F; Yin Z; Guo Y; Tasset C; Sundy JS; Jahreis A; Mozaffarian N; Messina OD; Landewé RB; Atsumi T; Burmester GR
Ann Rheum Dis; 2021 Jun; 80(6):727-738. PubMed ID: 33452004
[TBL] [Abstract][Full Text] [Related]
3. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Combe BG; Tanaka Y; Buch MH; Nash P; Burmester GR; Kivitz AJ; Bartok B; Pechonkina A; Xia K; Emoto K; Kano S; Hendrikx TK; Landewé RBM; Aletaha D
Rheumatol Ther; 2023 Feb; 10(1):53-70. PubMed ID: 36209441
[TBL] [Abstract][Full Text] [Related]
5. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Genovese M; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Gong Q; Tasset C; Takeuchi T
Mod Rheumatol; 2023 Jul; 33(4):668-679. PubMed ID: 35920102
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Bartok B; Pechonkina A; Kondo A; Yin Z; Guo Y; Tasset C; Sundy JS; Takeuchi T
Mod Rheumatol; 2022 Feb; 32(2):273-283. PubMed ID: 34910203
[TBL] [Abstract][Full Text] [Related]
8. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
[TBL] [Abstract][Full Text] [Related]
9. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
10. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
Tanaka Y; Atsumi T; Aletaha D; Bartok B; Pechonkina A; Han L; Emoto K; Kano S; Rajendran V; Takeuchi T
Rheumatol Ther; 2023 Feb; 10(1):161-185. PubMed ID: 36327094
[TBL] [Abstract][Full Text] [Related]
11. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop KL; Tanaka Y; Takeuchi T; Kivitz A; Matzkies F; Genovese MC; Jiang D; Chen K; Bartok B; Jahreis A; Besuyen R; Burmester GR; Gottenberg JE
Ann Rheum Dis; 2022 Feb; 81(2):184-192. PubMed ID: 34740884
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Guo Y; Tasset C; Sundy JS; Takeuchi T
Mod Rheumatol; 2022 Feb; 32(2):263-272. PubMed ID: 34910188
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses.
Tanaka Y; Takeuchi T; Atsumi T; Combe BG; Aletaha D; Kaise T; Rajendran V
Rheumatol Ther; 2023 Dec; 10(6):1399-1415. PubMed ID: 37668865
[TBL] [Abstract][Full Text] [Related]
14. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.
Curtis JR; Emery P; Downie B; Zhong Y; Liu J; Han L; Hawtin RE; Burmester GR
Rheumatol Ther; 2024 Feb; 11(1):177-189. PubMed ID: 38057656
[TBL] [Abstract][Full Text] [Related]
16. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
17. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
18. Impact of filgotinib on pain control in the phase 3 FINCH studies.
Taylor PC; Kavanaugh A; Nash P; Pope J; Pongratz G; Fautrel B; Alten R; Hasegawa K; Rao S; de Vries D; Stiers PJ; Watson C; Westhovens R
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38479751
[TBL] [Abstract][Full Text] [Related]
19. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
